Protagonist returns to Q1 FY26 profit; revenue rises to $56.37 million

Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc.

PTGX

0.00
  • Protagonist Therapeutics posted net income of USD 3.78 million, swinging from a net loss, with diluted EPS at USD 0.05.
  • Revenue climbed to USD 56.37 million, driven by a USD 50 million milestone tied to FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis.
  • Operating loss narrowed to USD 3.65 million as R&D expense rose to USD 46.74 million; G&A increased to USD 13.28 million.
  • Cash, cash equivalents and marketable securities totaled USD 620.33 million, with runway projected through at least 2028.
  • FDA set an August 2026 PDUFA goal date for rusfertide; Protagonist exercised its Takeda opt-out right, triggering a USD 200 million payment and lifting expected worldwide royalties to 14%-29%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagonist Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202605051605ACCESSWRNAPR_____1164003) on May 05, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.